Bausch Health Companies Inc. (BHC)

Market Cap	2.52B
Revenue (ttm)	9.86B
Net Income (ttm)	98.00M
Shares Out	369.80M
EPS (ttm)	0.27
PE Ratio	25.94
Forward PE	1.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,771,865
Open	6.81
Previous Close	6.78
Day's Range	6.73 - 7.02
52-Week Range	4.25 - 9.85
Beta	0.48
Analysts	Hold
Price Target	9.00 (+32.06%)
Earnings Date	Oct 29, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,700
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $9.0, which is an increase of 32.06% from the latest price.

Price Target

$9.0

(32.06% upside)

Analyst Consensus: Hold